Identification of mutations in epidermal growth factor receptor may predict response to gefitinib in NSCLC

Benzer Materyaller

• Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
  Yazar:: Singh, Charu
  Baskı/Yayın Bilgisi: (2014)
• Mutations of the epidermal growth factor receptor gene in NSCLC patients
  Yazar:: HAN, BING, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Oral gefitinib produces symptomatic and radiological benefit in advanced NSCLC
  Yazar:: Banerjee, A
  Baskı/Yayın Bilgisi: (2004)
• Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
  Yazar:: Kimura, H, ve diğerleri
  Baskı/Yayın Bilgisi: (2007)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  Yazar:: Zakowski, Maureen F., ve diğerleri
  Baskı/Yayın Bilgisi: (2009)